Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is an important therapeutic modality for patients with acute myelogenous leukemia (AML) with poor risk features. Nonetheless, roughly 30% of such patients have leukemia recurrence and up to 2% of these are donor-derived leukemias, in which malignancy develops in the donor’s transplanted cells, despite extremely low rates of leukemia in the donors themselves. Notably, over 20% of these malignancies carry chromosome 7 abnormalities nearly all of which are monosomies. Recent advances in whole exome and genome sequencing have allowed for detection of candidate genes that likely contribute to the development of AML in donor cells (donor leukemia, DCL). These genes include CEBPA, GATA2, JAK2, RUNX1, DDX41, EZH2, IDH1/2, DNMT3A, ASXL1, XPD, XRCC3, and CHEK1. The potential roles of variants in these genes are evaluated based on familial clustering of MDS/AML and corresponding animal studies demonstrating their leukemogenic nature. This review describes the spectrum of genetic aberrations detected in DCL cases in the literature with regard to the character of the individual cases, existing family cohorts that carry individual genes, and functional studies that support etiologic roles in AML development. DCL presents a unique opportunity to examine genetic variants in the donors and recipients with regards to progression to malignancy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cornelissen JJ, van Putten WLJ, Verdonck LF, Theobald M, Jacky E, Daenen SMG, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109:3658–66.
Rashidi A, Ebadi M, Colditz GA, DiPersio JF. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2016;22:651–7.
Horowitz M, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant. 2018;53:1379–89.
Wang E, Hutchinson CB, Huang Q, Lu CM, Crow J, Wang FF, et al. Donor cell–derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature. Am J Clin Pathol. 2011;135:525–40.
Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S, et al. Development of leukemia in donor cells after allogeneic stem cell transplantation-a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2005;90:969–75.
Engel N, Rovo A, Badoglio M, Labopin M, Basak GW, Beguin Y, et al. European experience and risk factor analysis of donor cell-derived leukaemias/MDS following haematopoietic cell transplantation. Leukemia. 2019;33:508–17.
Ruiz-Argüelles GJ, Ruiz-Delgado GJ, Garces-Eisele J, Ruiz-Arguelles A, Perez-Romano B, Reyes-Nuñez V. Donor cell leukemia after non-myeloablative allogeneic stem cell transplantation: a single institution experience. Leuk Lymphoma. 2006;47:1952–5.
Suárez-González J, Martínez-Laperche C, Kwon M, Balsalobre P, Carbonell D, Chicano M, et al. Donor cell-derived hematologic neoplasms after hematopoietic stem cell transplantation: a systematic review. Biol Blood Marrow Transplant. 2018;24:1505–13.
Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant. 2011;17:771–89.
Perz JB, Ritgen M, Moos M, Ho AD, Kneba M, Dreger P. Occurrence of donor-derived CLL 8 years after sibling donor SCT for CML. Bone Marrow Transplant. 2008;42:687–8.
Fiala M, Hucthagowder V, Westervelt P, Stockerl-Goldstein K, Kulkarni S, Ghobadi A. Two cases of donor-derived malignancies following allogeneic hematopoietic stem cell transplantation. Ann Hematol Oncol. 2015;2:1051.
Castleton AZ, Brazma D, Howard‐Reeves J, Chanalaris A, Glanville J, Nizetic D, et al. Genome gains at chromosome 21q21/22 segment leads to co-amplification of Down Syndrome Critical Regions and known oncogenes in a case of donor cell-derived acute myeloid leukaemia following allogeneic sex mismatched umbilical cord blood transplantation for chronic myeloid leukaemia. Br J Haematol. 2010;151:285–8.
Sala-Torra O, Hanna C, Loken MR, Flowers MED, Maris M, Ladne PA, et al. Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:511–7.
Fialkow PJ, Thomas ED, Bryant JI, Neiman PE. Leukaemic transformation of engrafted human marrow cells in vivo. Lancet. 1971;1:251–5.
Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008;35:418–29.
Wang L, Xiao H, Zhang X, Wang C, Huang H. The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. J Hematol Oncol. 2014;7:61.
Niederwieser DW, Appelbaum FR, Gastl G, Gersdorf E, Meister B, Geissler D, et al. Inadvertent transmission of a donor’s acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. N Engl J Med. 1990;322:1794–6.
Galera P, Hsu AP, Wang W, Droll S, Chen R, Schwartz JR, et al. Donor-derived MDS/AML in families with germline GATA2 mutation. Blood. 2018;132:1994–8.
Xiao H, Shi J, Luo Y, Tan Y, He J, Xie W, et al. First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2011;117:5257–60.
Yasuda T, Ueno T, Fukumura K, Yamato A, Ando M, Yamaguchi H, et al. Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia. 2014;28:426–8.
Hahn CN, Ross DM, Feng J, Beligaswatte A, Hiwase DK, Parker WT, et al. A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone. Leukemia. 2015;29:2101–4.
Herold S, Kuhn M, Bonin MV, Stange T, Platzbecker U, Radke J, et al. Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient. Leukemia. 2017;31:1637–40.
Liu Z, Liu H, Zhang Y, Kong D, Shi J, Zhang Y, et al. ASXL1-mutated donor HSCs evolved into FLT3-ITD positive AML in the unrelated donor and FLT3-ITD negative AML in the recipient after transplant. Blood. 2015;126:5403–5403.
Glasser L, Meloni-Ehrig A, Greaves W, Demel KC, Butera J. Synchronous development of acute myeloid leukemia in recipient and donor after allogeneic bone marrow transplantation: report of a case with comments on donor evaluation. Transfusion. 2009;49:555–62.
Orciuolo E, Azzarà A, Bandini G, Galimberti S, Bonifazi F, Fazzi R, et al. Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor. Bone Marrow Transplant. 2004;33:859–61.
Boulton-Jones R, Parker A, Hepburn M, Bowen DT. Secondary myelodysplasia of donor cell origin following nonmyeloablative sibling allogeneic stem cell transplantation. Bone Marrow Transplant. 2005;36:471–2.
Au WY, Chan EC, Siu LLP, Lau TCM, Lie AKW, Ma SK, et al. Leukaemic relapse of donor origin after allogeneic bone marrow transplantation from a donor who later developed bronchogenic carcinoma. Br J Haematol. 2002;119:777–80.
Bielorai B, Deeg HJ, Weintraub M, Neumann Y, Rosner E, Amariglio N, et al. B-cell lymphoma developing in the donor 9 years after donor-origin acute myeloid leukemia post bone marrow transplantation. Bone Marrow Transplant. 2003;31:931–4.
Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019;37:375–85.
Boettcher S, Wilk CM, Singer J, Beier F, Burcklen E, Beisel C, et al. Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020;135:1548–59.
Fraser CJ, Hirsch BA, Dayton V, Creer MH, Neglia JP, Wagner JE, et al. First report of donor cell–derived acute leukemia as a complication of umbilical cord blood transplantation. Blood. 2005;106:4377–80.
Dietz AC, DeFor TE, Brunstein CG Jr. Donor-derived myelodysplastic syndrome and acute leukaemia after allogeneic haematopoietic stem cell transplantation: incidence, natural history and treatment response. Br J Haematol. 2014;166:209–12.
Greaves M, Colman SM, Kearney L, Ford AM. Fusion genes in cord blood. Blood. 2011;117:369–70.
Kato M, Yamashita T, Suzuki R, Matsumoto K, Nishimori H, Takahashi S, et al. Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation. Leukemia. 2016;30:1742–5.
Brown AL, Hahn CN, Scott HS. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA). Blood. 2020;136:24–35.
McKenney AS, Lau AN, Somasundara AVH, Spitzer B, Intlekofer AM, Ahn J, et al. JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition. J Clin Investig. 2018;128:789.
Tawana K, Rio-Machin A, Preudhomme C, Fitzgibbon J. Familial CEBPA-mutated acute myeloid leukemia. Semin Hematol. 2017;54:87–93.
Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.
Bereshchenko O, Mancini E, Moore S, Bilbao D, Månsson R, Luc S, et al. Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPα mutant AML. Cancer Cell. 2009;16:390–400.
Wlodarski MW, Collin M, Horwitz MS. GATA2 deficiency and related myeloid neoplasms. Semin Hematol. 2017;54:81–6.
Fasan A, Eder C, Haferlach C, Grossmann V, Kohlmann A, Dicker F, et al. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Leukemia. 2013;27:482–5.
Yoshimitsu M, Hachiman M, Uchida Y, Arima N, Arai A, Kamada Y, et al. Essential thrombocytosis attributed to JAK2-T875N germline mutation. Int J Hematol. 2019;110:584–90.
Hirsch P, Mamez AC, Belhocine R, Lapusan S, Tang R, Suner L, et al. Clonal history of a cord blood donor cell leukemia with prenatal somatic JAK2 V617F mutation. Leukemia. 2016;30:1756–9.
Vicente C, Vázquez I, Marcotegui N, Conchillo A, Carranza C, Rivell G, et al. JAK2-V617F activating mutation in acute myeloid leukemia: prognostic impact and association with other molecular markers. Leukemia. 2007;21:2386–90.
Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17:584–96.
Sood R, Kamikubo Y, Liu P. Role of RUNX1 in hematological malignancies. Blood. 2017;129:2070–82.
Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood. 2008;112:4639–45.
Mendler JH, Maharry K, Radmacher MD, Mrózek K, Becker H, Metzeler KH, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol. 2012;30:3109–18.
Bera R, Chiu M-C, Huang Y-J, Lin T-H, Kuo M-C, Shih L-Y. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia. J Hematol Oncol. 2019;12:104.
Elfenbein GJ, Brogaonkar DS, Bias WB, Burns WH, Saral R, Sensenbrenner LL, et al. Cytogenetic evidence for recurrence of acute myelogenous leukemia after allogeneic bone marrow transplantation in donor hematopoietic cells. Blood. 1978;52:627–36.
Cooley LD, Sears DA, Udden MM, Harrison WR, Baker KR. Donor cell leukemia: report of a case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. Am J Hematol. 2000;63:46–53.
Brunstein CG, Hirsch BA, Hammerschmidt D, McGlennen RC, Nguyen PL, Verfaillie CM. Leukemia in donor cells after allogeneic hematopoietic stem cell transplant. Bone Marrow Transpl. 2002;29:999–1003.
Kobayashi S, Kobayashi A, Osawa Y, Nagao S, Takano K, Okada Y, et al. Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation. Leukemia. 2017;31:1020–2.
Maciejewski JP, Padgett RA, Brown AL, Müller-Tidow C. DDX41-related myeloid neoplasia. Semin Hematol. 2017;54:94–7.
Tsukamoto T, Gearhart MD, Kim S, Mekonnen G, Spike CA, Greenstein D. Insights into the involvement of spliceosomal mutations in myelodysplastic disorders from analysis of SACY-1/DDX41 in Caenorhabditis elegans. Genetics. 2020. https://doi.org/10.1534/genetics.119.302973.
Cedar H, Bergman Y, Linking DNA. methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10:295–304.
Asada S, Fujino T, Goyama S, Kitamura T. The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci. 2019;76:2511–23.
Yang L, Rau R, Goodell MA. DNMT3A in haematological malignancies. Nat Rev Cancer. 2015;15:152–65.
Mechaal A, Menif S, Abbes S, Safra I. EZH2 new diagnosis and prognosis marker in acute myeloid leukemia patients. Adv Med Sci. 2019;64:395–401.
Conway O’Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014;2014:e103175.
Yang Y, Akada H, Nath D, Hutchison RE, Mohi G. Loss of Ezh2 cooperates with Jak2V617F in the development of myelofibrosis in a mouse model of myeloproliferative neoplasm. Blood. 2016;127:3410–23.
Green CL, Evans CM, Zhao L, Hills RK, Burnett AK, Linch DC, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118:409–12.
Williams LS, Lai CE. Donor cell acute myeloid leukemia after transplant for follicular lymphoma. Blood. 2019;134:5697.
Clark O, Yen K, Mellinghoff IK. Molecular pathways: isocitrate dehydrogenase mutations in cancer. Clin Cancer Res. 2016;22:1837–42.
Rafei H, DiNardo CD. Hereditary myeloid malignancies. Best Pract Res Clin Haematol. 2019;32:163–76.
Diamond HR, Ornellas MH, Orfao A, Gomes BE, Campos MM, Fernandez TS, et al. Acute myeloid leukemia of donor origin after allogeneic stem cell transplantation from a sibling who harbors germline XPD and XRCC3 homozygous polymorphisms. J Hematol Oncol. 2011;4:39.
Seedhouse C, Bainton R, Lewis M, Harding A, Russell N, Das-Gupta E. The genotype distribution of the XRCC1gene indicates a role for base excision repair in the development of therapy-related acute myeloblastic leukemia. Blood. 2002;100:3761–6.
Dickson MA, Papadopoulos EB, Hedvat CV, Jhanwar SC, Brentjens RJ. Acute myeloid leukemia arising from a donor derived premalignant hematopoietic clone: a possible mechanism for the origin of leukemia in donor cells. Leuk Res Rep. 2014;3:38–41.
Shiozaki H, Yoshinaga K, Kondo T, Imai Y, Shiseki M, Mori N, et al. Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source. Bone Marrow Transplant. 2014;49:102–9.
Otero L, de Souza DC, de Cássia Tavares R, Gomes BE, Padilha TF, Bouzas LF, et al. Monosomy 7 in donor cell-derived leukemia after bone marrow transplantation for severe aplastic anemia: Report of a new case and review of the literature. Genet Mol Biol. 2012;35:734–6.
Goh K, Klemperer MR. In vivo leukemic transformation: cytogenetic evidence of in vivo leukemic transformation of engrafted marrow cells. Am J Hematol. 1977;2:283–90.
Browne PV, Lawler M, Humphries P, McCann SR. Donor-cell leukemia after bone marrow transplantation for severe aplastic anemia. N Engl J Med. 1991;325:710–3.
Lowsky R, Fyles G, Minden M, Lipton J, Meharchand J, Tejpar I, et al. Detection of donor cell derived acute myelogenous leukaemia in a patient transplanted for chronic myelogenous leukaemia using fluorescence in situ hybridization. Br J Haematol. 1996;93:163–5.
Witherspoon RP, Schubach W, Neiman P, Martin P, Thomas ED. Donor cell leukemia developing six years after marrow grafting for acute leukemia. Blood. 1985;65:1172–4.
Hambach L, Eder M, Dammann E, Battmer K, Stucki A, Heil G, et al. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant. 2001;28:705–7.
Lawler M, Locasciulli A, Longoni D, Schiro R, McCann SR. Leukaemic transformation of donor cells in a patient receiving a second allogeneic bone marrow transplant for severe aplastic anaemia. Bone Marrow Transplant. 2002;29:453–6.
Gopcsa L, Barta A, Banyai A, Konya M, Pajor L, Földi J, et al. Acute myeloid leukaemia of donor cell origin developing 5 years after allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplant. 2002;29:449–52.
Daly AS, Kamel-Reid S, Lipton JH, Messner HA, Kiss TL, Chun K, et al. Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia. Leuk Res. 2004;28:1107–11.
Matsunaga T, Murase K, Yoshida M, Fujimi A, Iyama S, Kuribayashi K, et al. Donor cell derived acute myeloid leukemia after allogeneic cord blood transplantation in a patient with adult T-cell lymphoma. Am J Hematol. 2005;79:294–8.
Reichard KK, Zhang Q-Y, Sanchez L, Hozier J, Viswanatha D, Foucar K. Acute myeloid leukemia of donor origin after allogeneic bone marrow transplantation for precursor T-cell acute lymphoblastic leukemia: Case report and review of the literature. Am J Hematol. 2006;81:178–85.
Pieroni F, Oliveira FM, Panepucci RA, Voltarelli JC, Simões BP, Falcão RP. Development of donor cell derived acute myeloid leukemia after stem cell transplantation for chronic myeloid leukemia. Bone Marrow Transpl. 2006;37:801–2.
Ataergin S, Arpaci F, Cetin T, Guran S, Yakicier C, Beyzadeoglu M, et al. Donor cell leukemia in a patient developing 11 months after an allogeneic bone marrow transplantation for chronic myeloid leukemia. Am J Hematol. 2006;81:370–3.
Havelange V, Antoine-Poirel H, Saussoy P, Van Den Neste E, Ferrant A. Donor cell leukemia developing after hematopoietic stem cell transplantation for multiple myeloma. Acta Clin Belg. 2006;61:82–6.
Ando T, Yujiri T, Mitani N, Takeuchi H, Nomiyama J, Suguchi M, et al. Donor cell-derived acute myeloid leukemia after unrelated umbilical cord blood transplantation. Leukemia. 2006;20:744–5.
Cetin Z, Tezcan G, Karauzum SB, Kupesiz A, Manguoglu AE, Yesilipek A, et al. Donor cell-derived acute myeloblastic leukemia after allogeneic peripheral blood hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol. 2006;28:763–7.
Stevens JM, Syndercombe-Court D, Oakervee HE, McCloskey D, Jenner MJ, Gribben JG, et al. Development of original donor cell leukemia after successful engraftment from a second donor. Blood. 2007;110:4621–2.
Jacobs JFM, Brons PP, Simons A, van der Reijden BA, Hoogerbrugge PM. Therapy-related, donor-derived AMLresponding to a second allogeneic BMT. Bone Marrow Transplant. 2007;40:499–500.
Hamaki T, Kajiwara K, Kami M, Murashige N, Funaki M, Harima A, et al. Donor cell-derived acute monoblastic leukemia involving MLL gene translocation in an adult patient who received umbilical cord blood transplantation. Bone Marrow Transplant. 2008;41:91–2.
Crow J, Youens K, Michalowski S, Perrine G, Emhart C, Johnson F, et al. Donor cell leukemia in umbilical cord blood transplant patients. J Mol Diagn. 2010;12:530–7.
Nagamura-Inoue T, Kodo H, Takahashi TA, Mugishima H, Tojo A, Asano S. Four cases of donor cell-derived AML following unrelated cord blood transplantation for adult patients: experiences of the Tokyo Cord Blood Bank. Cytotherapy. 2007;9:727–8.
Gustafsson B, Moell J, Leblanc K, Barbany G, Söderhäll S, Winiarski J. Donor cell-derived acute myeloid leukemia after second allogenic cord blood transplantation in a patient with Fanconi anemia. Pediatr Transplant. 2012;16:E241–5.
Adachi Y, Yamaguchi Y, Sagou K, Yamaga Y, Fukushima N, Ozeki K, et al. Acute megakaryoblastic leukemia developing as donor cell leukemia after umbilical cord blood transplantation. Intern Med. 2018;57:569–74.
Bouvier A, Ribourtout B, François S, Orvain C, Paz DL, Beucher A, et al. Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplantation. Eur J Haematol. 2018;101:570–4.
Wang H-C, Liu Y-C, Tsai Y-F, Wu C-H, Cho S-F, Hsiao H-H, et al. Donor cell-derived acute promyelocytic leukemia after allogeneic hematopoietic stem cell transplant. Ann Hematol. 2015;94:887–8.
Komeno Y, Kanda Y, Kandabashi K, Kawazu M, Goyama S, Takeshita M, et al. Reduced-intensity bone marrow transplantation from an alternative unrelated donor for myelodysplastic syndrome of first-donor origin. Am J Hematol. 2003;72:220–2.
Hamdi A, Afrough A, Muzzafar T, Popat UR, Hosing CM, Qazilbash MH, et al. Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease. Clin Lymphoma Myeloma Leuk. 2014;14:e151–5.
Yamazaki R, Nakasone H, Wada H, Sakamoto K, Ashizawa M, Sato M, et al. Recurrence of monoclonal gammopathy associated with donor-derived myelodysplastic syndrome after cord blood stem cell transplantation. Exp Hematol. 2011;39:1119–23.
Konuma T, Ooi J, Takahashi S, Tomonari A, Tsukada N, Kato S, et al. Donor cell-derived myelodysplastic syndrome after cord blood transplantation. Bone Marrow Transplant. 2009;43:429–31.
Sevilla J, Querol S, Molines A, González-Vicent M, Balas A, Carrió A, et al. Transient donor cell-derived myelodysplastic syndrome with monosomy 7 after unrelated cord blood transplantation. Eur J Haematol. 2006;77:259–63.
Hashino S, Fujisawa F, Kondo T, Imamura M, Sato K, Torimoto Y, et al. Donor-type myelodysplastic syndrome with t(2;3) and monosomy 7 after allogeneic peripheral blood stem cell transplantation and liver transplantation in a patient with severe-type aplastic anemia. Int J Hematol. 2006;84:363–6.
Beck C, Humpe A, Harder S, Schmid M, Horst HA. Myelodysplastic syndrome of donor origin subsequent to successful treatment of myeloid/NK-cell precursor leukaemia with allogeneic PBSCT: two very rare conditions in one patient. Ann Hematol. 2005;84:616–8.
Kraut L, Trebeljahr G, Thiele B, Fauser AA. Donor cell-derived myelodysplastic syndrome in a patient 7 years after unrelated allogeneic HLA-mismatched transplantation for Ph + chronic myeloid leukemia. Bone Marrow Transpl. 2005;36:737.
Lang Z, Dinndorf P, Ladisch S, Bayever E, Reaman G. Chromosomal transformation in donor cells following allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004;33:1253–6.
Komrokji R, Ifthikharuddin JJ, Felgar RE, Abboud CN, Wedow LA, Connaughton A, et al. Donor cell myelodysplastic syndrome after allogeneic stem cell transplantation responding to donor lymphocyte infusion: Case report and literature review. Am J Hematol. 2004;76:389–94.
Haltrich I, Müller J, Szabó J, Kovács G, Kóos R, Poros A, et al. Donor-cell myelodysplastic syndrome developing 13 years after marrow grafting for aplastic anemia. Cancer Genet Cytogenet. 2003;142:124–8.
Shekhter-Levin S, Bloom EJ, Swerdlow SH, Sherer ME, Wald N, Gollin SM. Acquired monosomy 7 in donor cells in a patient treated for acute lymphoblastic leukemia with bone marrow transplantation. Cancer Genet Cytogenet. 1997;95:190–7.
Cotter R, Najfeld V, Isola L, Del Toro G, Roman E, Petersen B, et al. An unusual case of donor-derived myelodysplastic syndrome following double-unit umbilical cord blood transplantation in acute lymphoblastic leukemia. Am J Hematol. 2012;87:931–3.
Brás G, Pinho-Vaz C, Campos A. Donor-cell origin high-risk myelodysplastic syndrome synchronous with an intracranial meningioma-like tumor, 8 years after allogeneic hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Case Rep Med. 2017;2017:9674385.
Ho ESK, Chow HCH, Chan CTL, Luo R, Leung HCM, Yiu SM, et al. Whole genome sequencing on donor cell leukemia in a patient with multiple myeloma identified gene mutations that may provide insights to leukemogenesis. Blood. 2012;120:2414.
Ogawa S. Genetics of MDS. Blood. 2019;133:1049–59.
Assi R, Mahfouz R, Owen R, Gunthorpe M, Chehab FF, Bazarbachi A. PAX5, NOTCH3, CBFB, and ACD drive an activated RAS pathway and monosomy 7 to B-ALL and AML in donor cell leukemia. Bone Marrow Transplant. 2019;54:1124–8.
Bobadilla-Morales L, Pimentel-Gutiérrez HJ, Gallegos-Castorena S, Paniagua-Padilla JA, Ortega-de-la-Torre C, Sánchez-Zubieta F, et al. Pediatric donor cell leukemia after allogeneic hematopoietic stem cell transplantation in AML patient from related donor. Mol Cytogenet. 2015;8. https://doi.org/10.1186/s13039-014-0105-4.
Luber V, Lutz M, Thiede C, Haferlach C, Dürk HA, Einsele H, et al. Donor-cell leukemia with novel genetic features 2 years after sex-mismatched T cell-depleted haploidentical stem cell transplantation. Ann Hematol. 2020;99:899–901.
Schwartz JR, Walsh MP, Ma J, Lamprecht T, Wang S, Wu G, et al. Clonal dynamics of donor-derived myelodysplastic syndrome after unrelated hematopoietic cell transplantation for high-risk pediatric B-lymphoblastic leukemia. Cold Spring Harb Mol Case Stud. 2018;4. https://doi.org/10.1101/mcs.a002980.
Rodríguez-Macías G, Martínez-Laperche C, Gayoso J, Noriega V, Serrano D, Balsalobre P, et al. Mutation of the NPM1 gene contributes to the development of donor cell-derived acute myeloid leukemia after unrelated cord blood transplantation for acute lymphoblastic leukemia. Hum Pathol. 2013;44:1696–9.
Chonabayashi K, Kondo T, Yamamoto K, Tanaka Y, Nagai Y, Hishizawa M, et al. Successful use of second cord blood transplantation to achieve long-term remission in cord blood donor cell-derived AML harboring a FLT3-ITD and an NPM1 mutation. Bone Marrow Transpl. 2012;47:1252–3.
Taniguchi R, Muramatsu H, Okuno Y, Suzuki K, Obu S, Nakatochi M et al. Comprehensive genetic analysis of donor cell derived leukemia with KMT2A rearrangement. Pediatr Blood Cancer. 2018;65. https://doi.org/10.1002/pbc.26823.
Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, Artz A, et al. Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donor-derived malignancy. Biol Blood Marrow Transplant. 2016;22:2100–3.
Author information
Authors and Affiliations
Contributions
CL developed the idea and format for the review. LW constructed all the tables. CL, LW, KD, and JEK all contributed equally to the writing and approval of the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
CL has served on an advisory board for Abbvie, Agios, Daiichi-Sankyo, Macrogenics and Jazz Pharmaceuticals and as a speaker for Astellas and Jazz Pharmaceuticals. LW, KD and JEK declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Williams, L., Doucette, K., Karp, J.E. et al. Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome. Bone Marrow Transplant 56, 1535–1549 (2021). https://doi.org/10.1038/s41409-021-01214-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-021-01214-z
This article is cited by
-
International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update
Bone Marrow Transplantation (2024)
-
Donor cell-derived genetic abnormalities after sex mismatched allogeneic cell transplantation: a unique challenge of donor cell leukemia
Blood Cancer Journal (2023)